Drug Database
MO

mometasone furoate (Monovo / H527722 / Mundoson)

✓ Approved

Almirall, S.A · NR3C1 · 小分子

什么是 mometasone furoate?

mometasone furoate 是一种小分子,由Almirall, S.A研发。该药已获批,用于治疗相关适应症,给药途径:Topical。

药物档案

商品名Monovo, H527722, Mundoson
公司Almirall, S.A
药物类别小分子
分子靶点NR3C1, NR3C2
给药途径Topical
状态Approved

作用机制

分子靶点

mometasone furoate 作用于 2 个分子靶点:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
NR3C2nuclear receptor subfamily 3 group C member 2 (NR3C2VIT, MR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

mometasone furoate 针对 3 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersDermatitis allergic✓ Approved
Skin and subcutaneous tissue disordersDermatitis atopic✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

相关研究文献

PubMedVestnik otorinolaringologii2026-11-18

[Possibilities of combined topical intranasal glucocorticosteroid and antihistamine therapy in the treatment of allergic rhinitis for the relief of nasal obstruction and hyposmia].

Baranov K K KK, Kotova E N EN, Vyazmenov E O EO, Polunin M M MM et al.

Nasal obstruction and hyposmia are key symptoms of both allergic inflammation of the nasal mucosa and acute sinusitis/adenoiditis. The issue of optimal maintenance therapy after resolution of the acute process, especially in patients with AR, remains debatable. To evaluate the efficacy of mometasone furoate monotherapy and combined therapy with mometasone furoate and olopatadine in children and adults with seasonal and perennial AR complicated by acute sinusitis, with regard to the dynamics of nasal obstruction and olfactory function. A prospective comparative study was conducted in patients with seasonal and perennial allergic rhinitis complicated by acute sinusitis, with assessment of the dynamics of nasal obstruction and olfactory dysfunction. The study included 240 patients aged 6 to 60 years. After resolution of acute rhinosinusitis, the patients were assigned to observation groups and continued treatment for 1 month: group 1 received intranasal mometasone furoate 100-200 μg/day; group 2 received a combined mometasone furoate+olopatadine preparation according to the instructions for use; group 3 (control) received no maintenance antiallergic therapy. Treatment efficacy was assessed by evaluating nasal obstruction and olfactory function. A direct relationship was found between recovery of olfaction and nasal breathing and the selected maintenance therapy regimen after acute sinusitis. The combined approach (MF+O) was the most effective method, providing recovery of olfaction in 78% of patients (p<0.001). Combined topical therapy with INCS and an antihistamine has an advantage in reducing nasal obstruction and restoring olfaction compared with standard therapy or no maintenance antiallergic therapy. The findings support the feasibility of including combined topical preparations in treatment algorithms for patients with AR complicated by acute sinusitis.

PMID 43046751
阅读全文 →
PubMedRespiratory research2026-11-17

Uncovering the heterogeneous effect of inhaled corticosteroids on COPD exacerbations with causal machine learning.

Huts Helene H, Verstraete Kenneth K, Strypsteen Thomas T, Gyselinck Iwein I et al.

High blood eosinophil counts can predict an enhanced response to inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD), but additional insight in treatment effect heterogeneity is needed to optimize clinical disease management. We investigated if causal machine learning models can detect heterogeneity in the effect of two ICS-containing therapies on both time to first exacerbation and exacerbation rate, and if this approach can identify additional predictors of ICS response. Baseline characteristics from patients in the fluticasone furoate/umeclidinium/vilanterol (FF/U/V) and U/V arms of the InforMing the PAthway of COPD Treatment (IMPACT) trial (ClinicalTrials.gov identifier NCT02164513) were used to train a causal survival forest to estimate the effect of fluticasone furoate (an ICS) on time to first exacerbation for each patient. Similarly, a causal forest was trained for exacerbation rate. Results were averaged over 100 train and validation sets in a Monte-Carlo cross-validation approach. The analysis was repeated for a comparison of the FF/V and U/V arms. This analysis included 4048 FF/U/V, 4034 FF/V and 2025 U/V patients. Significant p-values for AUTOC (area under the targeting operator characteristic) curve indicated that all models ranked patients well according to individualized treatment and that significant heterogeneity was detected in the effect of ICS on both exacerbation outcomes. Respiratory symptoms, reversibility of airflow limitation and lung function, in addition to eosinophils, were identified as important predictors by all models. The contribution of additional predictors in determining the effect of ICS was most apparent for patients at the lower end of the eosinophil spectrum. This hypothesis-generating secondary analysis of IMPACT detected significant heterogeneity in the effect of ICS and indicated that, in addition to eosinophils, other clinical patient characteristics also contribute to the prediction of ICS response on both time to first exacerbation and exacerbation rate. The causal machine learning approach in this analysis can identify treatment effect predictors and patterns of response, to enhance insight in COPD disease phenotypes and heterogeneous treatment effects.

PMID 43040297
阅读全文 →
PubMedAdvances in therapy2026-11-16

Stepping up from ICS/LABA to FF/UMEC/VI in Patients with Uncontrolled Asthma: Outcomes from the 52-Week PERFORM Pragmatic Randomized Controlled Trial.

Oppenheimer John J JJ, Penz Erika E, Baptist Alan P AP, Garcia Gabriel G et al.

Asthma remains uncontrolled in many patients receiving inhaled corticosteroid/long-acting β2-agonist (ICS/LABA), suggesting that guideline-recommended escalation to triple therapy is often delayed. We report outcomes in patients with uncontrolled, infrequently exacerbating asthma (understudied in traditional randomized controlled trials) stepping up from ICS/LABA to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) from the PERFORM trial. PERFORM, a randomized, open-label, active-controlled, pragmatic trial in symptomatic adults with uncontrolled, infrequently exacerbating asthma, evaluated the effectiveness and safety of FF/UMEC/VI versus usual care ICS/LABA. Outcomes included trough forced expiratory volume in 1 s (FEV1), asthma control (Asthma Control Questionnaire [ACQ-5/-6/-7]), and achieving clinical remission at Week 52 for the step-up (participants treated with ICS/LABA pre-randomization) and overall population. Safety was assessed throughout the study. Overall, 783 of 1236 participants in PERFORM received ICS/LABA pre-randomization, with 392 and 391 randomized to FF/UMEC/VI and ICS/LABA, respectively. Statistically significant improvements in trough FEV1 were observed for FF/UMEC/VI versus ICS/LABA at Week 24 and were durable to Week 52 (least squares means treatment difference in change from baseline [95% confidence interval (CI)]: 66 ml [29, 103] and 67 ml [28, 106] at Weeks 24 and 52). FF/UMEC/VI showed greater odds of achieving ≥ 0.5-point improvement from baseline in ACQ-7 total score at Week 24 and achieving clinical remission at Week 52 versus ICS/LABA (adjusted odds ratio [95% CI]: 1.54 [1.12, 2.12] and 2.78 [1.82, 4.24]; not multiplicity adjusted). Results (including the Week 52 safety profile) were similar to the overall PERFORM population. Escalation to FF/UMEC/VI from ICS/LABA improved lung function, asthma control, and clinical remission, with no unexpected safety findings versus usual care ICS/LABA at Weeks 24 and 52, consistent with the overall PERFORM population. Initiation with FF/UMEC/VI may address the unmet need for optimized treatment in patients with uncontrolled, infrequently exacerbating asthma. GSK ID: 219912/NCT06372496. Supplementary file1 (MP4 149035 KB).

PMID 43037944
阅读全文 →
PubMedJournal of clinical medicine2026-11-14

Intranasal Mometasone After External Dacryocystorhinostomy-Necessity or Convention? A Retrospective Two-Centre Cohort Study.

Ortega-Evangelio Leticia L, Roig-Ferreruela Gonzalo G, Peris-Martínez Cristina C

Background/Objectives: Intranasal corticosteroids are frequently prescribed after dacryocystorhinostomy (DCR) to modulate mucosal healing and prevent ostium closure, but evidence supporting their use after external DCR (EXT-DCR) is scarce. This study compared early anatomical success after EXT-DCR under two centre-specific postoperative protocols that differed in the use of intranasal mometasone. Methods: Retrospective comparative cohort study of 243 consecutive EXT-DCR procedures (211 patients) for distal lacrimal obstruction performed by a single surgeon using the same technique at two centres between 2019 and 2025. Postoperative treatment was determined by each centre's standing protocol: both included oral amoxicillin-clavulanic acid for one week, and one centre additionally prescribed intranasal mometasone furoate twice daily for two months (mometasone group, n = 64; control group, n = 179). The primary outcome was anatomical success, defined as lacrimal patency on irrigation at two months. Groups were compared with Fisher's exact test and a multivariable logistic regression adjusted for age and sex. Results: Anatomical success was 93.8% (60/64) in the mometasone group and 89.9% (161/179) in the control group (absolute difference 3.8 percentage points; 95% CI -5.7 to 10.3; p = 0.45). After adjustment for age and sex, treatment group was not significantly associated with success (control vs. mometasone: OR 0.57; 95% CI 0.18-1.77; p = 0.33). No statistically significant associations were detected for age or sex. Conclusions: In this cohort, adding a two-month course of intranasal mometasone to standard postoperative care after EXT-DCR was not associated with a statistically significant improvement in early anatomical success. Given the limited statistical power and a confidence interval that does not exclude a clinically meaningful benefit, this absence of a significant difference does not establish therapeutic equivalence. Adequately powered prospective trials with longer follow-up are needed before routine intranasal corticosteroid use after EXT-DCR can be either recommended or abandoned.

PMID 43030648
阅读全文 →
PubMedFrontiers in veterinary science2026-11-13

Randomized comparative field clinical trial of hydrocortisone aceponate/gentamicin/miconazole otic suspension vs. mometasone furoate/florfenicol/terbinafine otic solution for the treatment of canine otitis externa.

Griffin J J, von Simson C C, Poincelot L L, Jasmin P P

This randomized, masked, multi-center field clinical trial compared two otic formulations: a gentamicin, miconazole, and hydrocortisone aceponate otic suspension (Easotic™, Virbac) administered once daily for five days, and a single-dose florfenicol, terbinafine, and mometasone furoate otic solution (Claro™, Elanco). Eighty-six client-owned dogs with acute otitis externa (OTIS3 score ≥ 5) were evaluated at 4 h post-application and on Days 2, 7, and 28. Based on the percentage of dogs achieving an OTIS3 score ≤ 3 at Day 28, both treatments (Easotic™ vs. Claro™) showed high efficacy (Intention-to-Treat (ITT): 85% vs. 79%, p = 0.400; Per Protocol (PP): 94% vs. 88%, p = 0.261). Easotic™ demonstrated a higher percentage of OTIS3 score reduction compared to Claro™ from Day 2. At Day 2, Easotic™ achieved greater improvements in ear discharge, odor, dirtiness, and stenosis compared to Claro™. Veterinarians' overall assessment of "Excellent" response was higher for Easotic™ at Day 7 (ITT: 50% vs. 26%, p = 0.009; PP: 49% vs. 29%, p = 0.010) and Day 28 (ITT: 62% vs. 36%, p = 0.017; PP: 76% vs. 44%, p = 0.002;). Similarly, 91% of the owners assessed the response to treatment as "Good" or "Excellent" with Easotic™, and 89% with Claro™. Notwithstanding the differences in dosing regimens, both products received comparable evaluations from owners regarding their physical and functional characteristics. The results of this study confirm the efficacy of Easotic™ in the management of otitis externa, notably to reduce ear discharge, stenosis, odor and dirtiness from Day 2.

PMID 43022469
阅读全文 →
PubMedJAMA network open2026-11-10

Inhaled Corticosteroids and Sickle Cell Disease Severity in Adults Without Asthma: A Randomized Clinical Trial.

Curtis Susanna A SA, McCuskee Sarah S, Cohen Robyn T RT, Liu Angela A et al.

People living with sickle cell disease (SCD) who have episodic cough and wheeze (ECW) without a diagnosis of asthma have high rates of pain episodes and acute chest syndrome. A previous trial, in which patients with SCD and ECW without asthma received 15 weeks of inhaled mometasone or placebo, showed that inhaled mometasone improved daily pain and reduced soluble vascular cell adhesion molecule 1 (VCAM-1), a marker of disease severity in SCD. To examine the biologic effects and safety of long-term daily inhaled mometasone in patients without asthma but with SCD and ECW. This placebo-controlled randomized clinical trial recruited patients with SCD from December 2018 to May 2022. Participants were randomly assigned to receive either inhaled mometasone or placebo for 48 weeks. Data analyses followed the modified intention-to-treat principle and were performed between July and November 2023. The inhaled mometasone group received 220 μg of inhaled mometasone furoate dry powder once daily. The placebo group received a matching placebo inhaler. The primary outcome was percentage change in soluble VCAM-1 levels from baseline to end of study. Secondary outcomes included laboratory results, functional outcomes, patient-reported outcomes, and health care utilization. Of the 77 patients who received the intervention and were included in the analysis, 40 were assigned to inhaled mometasone (mean [SD] age, 36.0 [11.6] years; 26 females [65%]) and 37 were assigned to placebo (mean [SD] age, 31.5 [8.6] years; 19 males [51%]). Compared with the placebo group, the inhaled mometasone group increased their soluble VCAM-1 levels by 42% (95% CI, -11% to 96%; P = .02). Point estimates for clinical outcomes favored the placebo group, although the findings were not statistically significant. In this trial of adults with SCD and ECW, extended courses of inhaled mometasone were associated with worsened markers of disease severity. Inhaled mometasone should not be used long-term in patients with SCD and ECW without a definitive diagnosis of asthma. ClinicalTrials.gov Identifier: NCT03758950.

PMID 43007675
阅读全文 →

注册免费账户还可查看另外 2149 篇文献

免费注册查看全部文献 →

了解更多mometasone furoate